Description: GlobeImmune, Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company's segment is the business of developing and commercializing various biopharmaceutical products. The Company's infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection. The Company's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, and GI-4000, which is in Phase IIb for the treatment of Resected pancreas cancer, and in Phase II for the treatment of Non-small cell lung cancer and colorectal cancer.
Home Page: www.globeimmune.com
1450 Infinite Drive
Louisville,
CO
80027
United States
Phone:
303 625 2700
Officers
| Name | Title |
|---|---|
| Mr. C. Jeffrey Dekker CPA | Pres, VP of Fin., Treasurer & Sec. |
| Dr. Richard C. Duke | Scientific Founder & Member of Scientific Advisory Board |
| Dr. Donald Bellgrau | Scientific Founder & Chairman of The Scientific Advisory Board |
| Mr. Thomas A. Keuer | Acting Head of Manufacturing Operations |
| Dr. Allen L. Cohn M.D. | Exec. Director Clinical Devel. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0.324 |
| IPO Date: | 2014-07-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |